Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Jul 22, 2026
Fabrinet (FN) Declines -14.5% Over 30 Days: Profit-Taking Meets Sector Rotation

Fabrinet (FN) Declines -14.5% Over 30 Days: Profit-Taking Meets Sector Rotation

Key Takeaways

  • Fabrinet (FN) shares declined approximately 14.5% over the last 30 days, falling from $617.09 on June 22, 2026, to $527.35 on July 21, 2026.
  • The 30-day slide extends a broader downtrend that has seen the stock lose roughly 23.6% over the last quarter and approximately 29.6% from its 52-week high of $748.89 reached on May 14, 2026.
  • Profit-taking following an extraordinary rally, combined with analyst downgrades and broader sector rotation out of high-valuation AI hardware names, fueled the selloff.
  • Despite the pullback, Fabrinet's underlying business remains strong: record Q3 FY2026 revenue of $1.21 billion represented 39.3% year-over-year growth, and Q4 guidance calls for continued expansion.
  • Wall Street maintains a consensus "Moderate Buy" rating with an average price target of $661.75, suggesting significant upside potential from current levels.

Fabrinet's Business and Market Position

Fabrinet is a leading global provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers (OEMs) of complex products. Headquartered in the Cayman Islands with principal operations in Thailand, the company specializes in high-complexity, high-mix manufacturing for customers across optical communications, data centers, automotive, industrial lasers, medical devices, and semiconductor capital equipment markets. Fabrinet's core competitive advantage lies in its ability to deliver precision manufacturing at scale for next-generation optical components, including coherent optical transceivers and modules critical to hyperscale data center and AI infrastructure buildouts. With a market capitalization of approximately $17.7 billion and institutional ownership exceeding 97%, FN is widely followed by investors seeking exposure to the AI-driven optical networking supply chain.

Recent Stock Performance: 30 Days and the Broader Quarter

Over the last 30 calendar days, Fabrinet shares fell from a closing price of $617.09 on June 22, 2026, to $527.35 on July 21, 2026, representing a decline of approximately 14.5%. The selloff was marked by heightened volatility, with the stock touching an intraday low of $440.02 on July 17 before rebounding sharply in the final sessions of the period. During the final two trading days captured, FN surged from $494.26 to $527.35, a gain of 6.7%, signaling that buyers stepped in near the lower end of the range. I also checked this using Tickeron’s AI Pattern Search Engine to see how the price action compared to similar setups in the sector.

Zooming out to the last quarter, the stock has declined roughly 23.6% from its April 22 close of $690.06. The quarterly performance reflects a sharp reversal from the stock's 52-week high of $748.89 on May 14, 2026, after which a broad-based correction took hold. The 50-day moving average has fallen to approximately $595, while the 200-day moving average sits near $564, indicating that the stock is now trading below both key technical levels — a signal that has historically attracted value-oriented institutional buyers to the name.

Factors Behind the 30-Day Decline

Several interconnected factors drove Fabrinet's 14.5% decline over the past 30 days. First, the stock entered the period already under significant selling pressure from its May peak, and momentum-driven traders continued to unwind positions as technical support levels gave way. The break below the psychologically important $600 level in mid-June accelerated algorithmic and stop-loss selling.

Second, analyst sentiment shifted notably during this window. On June 15, Zacks Research downgraded Fabrinet from "Strong-Buy" to "Hold," citing valuation concerns following the stock's extraordinary run. On June 30, Weiss Ratings lowered its rating from "Buy (B)" to "Buy (B-)," reflecting increased caution about near-term price sensitivity. These downgrades, while not catastrophic, added to the narrative that the stock had become overextended relative to near-term earnings visibility.

Third, broader macroeconomic headwinds — including uncertainty around tariff policy, persistent inflation concerns, and a rotation out of high-multiple technology stocks — disproportionately affected high-beta names like Fabrinet. The stock's beta of 1.20 amplified downside moves during sector-wide selloffs in the technology hardware space.

Finally, an insider sale by Director Homa Bahrami, who sold 2,500 shares at $711.91 on May 22 for approximately $1.78 million, remained a point of discussion among retail and institutional investors navigating the stock's correction, even as the transaction represented only a 13.4% reduction in the director's holdings.

The Story of the Last Quarter

The last quarter tells a story of two distinct halves. Fabrinet shares rallied powerfully through late April and into mid-May, culminating in a 52-week high of $748.89 on May 14, 2026. This surge was fueled by exceptional Q3 FY2026 earnings reported on May 4, which delivered non-GAAP EPS of $3.72 — beating consensus estimates by $0.14 — alongside record quarterly revenue of $1.21 billion, up 39.3% year-over-year. Management's Q4 guidance of $1.25 billion to $1.29 billion in revenue and non-GAAP EPS of $3.72 to $3.87 reinforced the bullish thesis around AI-driven optical demand.

However, the rally proved unsustainable at those levels. Beginning in the second half of May, a convergence of headwinds — including JPMorgan's neutral rating and $680 price target (May 5), Fox Advisors' downgrade from "Strong-Buy" to "Equal Weight" (May 5), tariff-related anxieties, and a broader sector rotation away from richly valued AI hardware stocks — triggered an aggressive round of profit-taking. The stock subsequently gave back the majority of its post-earnings gains, sliding from $748.89 to the mid-$400s by mid-July, before a modest recovery in the final week of the quarter brought shares back above $520.

AI Tools for Navigating Market Volatility

In navigating volatile markets like the one currently affecting Fabrinet and the broader technology sector, many traders turn to AI-driven tools for data-backed decision-making. Tickeron's Trending AI Robots page offers a curated selection of top-performing AI trading bots from a much larger universe of hundreds of bots trading thousands of tickers. These bots employ diverse strategies — ranging from swing trading and trend following to mean reversion and breakout detection — across multiple timeframes and asset classes. Each bot shown in the trending section is filtered based on recent performance metrics, providing traders with a transparent view of which automated strategies are currently delivering results. For investors looking to complement their own research with quantitative, AI-generated signals, exploring the Trending AI Robots page can be a practical starting point. I find this resource particularly useful when assessing how automated strategies are responding to names like FN amid sector shifts.

Key Drivers to Watch Going Forward

Looking ahead, several key catalysts will determine Fabrinet's trajectory. First and foremost, the company's Q4 FY2026 earnings report — covering the quarter ended June 26, 2026 — is expected in August and will be closely scrutinized. Investors will assess whether revenue landed within the guided range of $1.25 billion to $1.29 billion and whether non-GAAP EPS met the $3.72 to $3.87 target. Any deviation from these figures could produce outsized price moves.

Beyond earnings, Fabrinet's strategic investment in Raytek Semiconductor positions the company to capture next-generation demand for co-packaged optics, a technology increasingly viewed as essential for future AI data center architectures. Management commentary around datacom customer agreements and optical component demand trends will be pivotal. On the macro front, tariff developments, Federal Reserve policy, and sector-level fund flows into or out of technology hardware will continue to influence valuation multiples. With the average analyst price target of $661.75 still well above current levels, the market's willingness to re-rate the stock will ultimately depend on execution and sustained demand visibility in the optical infrastructure supply chain. One thing that stands out is how closely earnings execution will need to align with guidance to support any re-rating.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FN

Momentum Indicator for FN turns positive, indicating new upward trend

FN saw its Momentum Indicator move above the 0 level on August 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FN's RSI Indicator exited the oversold zone, of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for FN just turned positive on August 04, 2026. Looking at past instances where FN's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where FN advanced for three days, in of 333 cases, the price rose further within the following month. The odds of a continued upward trend are .

FN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FN entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. FN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.453) is normal, around the industry mean (6.338). P/E Ratio (46.731) is within average values for comparable stocks, (95.908). FN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.341). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (4.647) is also within normal values, averaging (5.350).

Notable companies

The most notable companies in this group are Corning (NYSE:GLW), Universal Display Corp (NASDAQ:OLED).

Industry description

The Electronic Components industry produces electronic equipment for industries and consumer electronics products, such as mobile devices, televisions, and circuit boards. TE Connectivity Ltd, for example, is a company that designs and manufactures connectivity and sensor products for harsh environments in various industries, such as automotive, industrial equipment, aerospace, and oil & gas. Another major player, Corning Inc., makes advanced optics including end-to-end fiber and wireless solutions for communications networks along with various other technologies catering to industrial and scientific applications.

Market Cap

The average market capitalization across the Electronic Components Industry is 14.12B. The market cap for tickers in the group ranges from 669 to 210.36B. APH holds the highest valuation in this group at 210.36B. The lowest valued company is MMATQ at 669.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Components Industry was 11%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 17%. GAUZ experienced the highest price growth at 42%, while CLS experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Electronic Components Industry was 208%. For the same stocks of the Industry, the average monthly volume growth was 306% and the average quarterly volume growth was 195%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 47
Price Growth Rating: 49
SMR Rating: 73
Profit Risk Rating: 65
Seasonality Score: -23 (-100 ... +100)
View a ticker or compare two or three
FN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of precision optical, electro-mechanical and electronic manufacturing services

Industry ElectronicComponents

Profile
Details
Industry
Electronic Components
Address
C/o Intertrust Corporate Services (Cayman) Limited
Phone
+1 662 524-9600
Employees
14663
Web
https://www.fabrinet.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Fabrinet (FN) Declines -14.5% Over 30 Days: Profit-Taking Meets Sector Rotation